9th Annual Cell Line Development & Engineering Asia & 10th Annual Biomanufacturing Agenda

Day 1: 3 November 2020

Chairperson’s Opening Remarks

Chen Guang, Consultant, Agency for Science, Technology and Research (A*STAR), Singapore

Joint Opening Plenary

Keynote Address:
China’s Big Leap towards BioPharma 2030  Innovation, Industrialization, Internationalization

Dr. Song Ru Lin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

Venture Capitals’ Roundtable:  
Show Me the Drug

  • Investment landscape in the Chinese biopharma market
  • Evaluating drug pipelines and development prospects
  • Mergers, expansion and JVs – Where do we see transactions picking up?
  • Financing new plants, new therapeutics, product launch and scaling-up operations – How do we review?
  • Manufacturing 4.0 – How do VCs and banks play a part in modernising the value chain?

Judith Li, Partner, Lilly Asia Ventures, China

Rani Jarkas, Chairman, Cedrus Group, Hong Kong
Lynn Yang, Managing Director, Sequoia Capital, China
Michael Xue, Managing Director, Morningside Ventures, China

Industry Spotlight:
Addressing Complex Protein Challenges with Lonza’s GS Xceed® Toolbox

Dr. Allison Porter, Head of Expression System Sciences, Lonza Pharma & Biotech, U.K.

Online Networking & Stretch Break

End of Joint Opening Plenary and 9th Annual Cell Line Development & Engineering Asia & 10th Annual Biomanufacturing commences

Innovative Bioprocess Development

Powder Handling and Hydration in Upstream Processes  

  • Evaluation of powder transfer bag designs for solid media and buffer handling
  • Trusted Weight Bags and streamlining incoming sampling requirements
  • Novel method for eliminating vortex mixing of powders
  • Supply chain security and supplier performance for a single use supplier

Scott Patterson, Vice President, Pharma / Biopharma, Technical Support, ILC Dover, Singapore

CMC development of Antibody Drug Conjugates

  • ADC introduction + ADC CMC challenge and approach

Dr. Huang Peng, Project Leader, ADC, TOT BIOPHARM, China

End of Conference Day 1

Day 2: 4 November 2020

Novel Advances In CLD Techniques & Technology

Chairperson’s Opening Remarks

Eric Chang, Head, Cell Line Development, JHL Biotech, China

Next-Generation Cell Line Development with Accelerated Timeline and High Productivity

  • Cell line development strategy for accelerated Covid-19 program approval
  • Codon impact on productivity
  • Next-generation sequencing application in cell line development

Zheng Zhang, Director II, Cell Line Development, WuXi Biologics, China

Single Cell Confidence – Creating the Double Lock of Assurance

Mark Stockdale, Amalgamator of Business and Biology, Solentim, UK

Using Recombinant Insulin in DoE for Media Development

  • Case study
  • Insulin – CHO Mab
  • Insulin – HEK293 Influenza Virus

Chantale Julien, Global Product Manager, Novo Nordisk Pharmatech, Denmark

Online Networking & Stretch Break

Difficult-to-Express Proteins Benefitting From Human Cells as a Production System

Dr. Vicky Goralczyk, Director, Cell Line and Bioprocess Development, Glycotope, Germany  

Next-Generation Cell Line Development Platform for Advanced Bispecific Antibodies Expression

Dr. Séverine Fagète, Vice President, Cell Line Development Services, Selexis, SA, Switzerland

End of Conference Day 2

Day 3: 5 November 2020

Biomanufacturing 2030 – China’s Great Leap

Scaling Up the Commercial Production of mAb Therapeutics in China

  • China’s capacity outlook and how do we capitalize on the mAb therapeutics markets
  • Teruisi’s breakthrough of mAb’s tech transfer and large-scale production in China while in-line with international standards – challenges and key learnings
  • Manufacture showcase to improve cost and efficiency

Dr. Wu You Ling, Chief Executive Officer, Zhejiang Teruisi Pharmaceuticals, China

Build vs. Buy – Long-term View of Capacity, Supply-Demand Balance and Investment in China’s Manufacturing Facilities

  • Insights on biopharma market segments driving new growth and where is the supply and demand
  • Identifying new market for biomanufacturing – emerging locations and site selection strategy
  • Manufacturing capacity outlook – utilization rates, new investment and a medium-term position
  • Commercial phase market outlook for CDMOs in China

Fireside Chat:
Jeff Li, General Manager, Lonza Pharma Biotech and Nutrition, China
Kevin Yang, Vice President, CMC and Manufacturing, I-MAB Biopharma, China

Online Networking & Stretch Break

Future Facilities & Smart Biomanufacturing

Tools and Best Practices for Successful Technology Transfer

Mahalia Corrales, Senior Director, Process Development & Technology, JHL Biotech, Taiwan

Manufacturing Technology Showcases – Improving Cost and Efficiency

  • Next gen manufacturing facilities design and investment trends
  • Smart automation case studies to increase facility efficiency and cost optimization
  • Intelligent bioreactors – advantages and benefits

Frank Ye, Senior Vice President, Technical Operations, Transcenta, China

Biomanufacturing Process Validation and Quality Risk Management

  • New process concepts of CQAs, CPPs, and QbDs
  • Best practices on quality risk management in bioprocess development
  • Case study on Bio-Thera’s manufacturing process quality control on the newest Humira biosimilar

Bao Cai, Senior Director, Manufacturing, Bio-Thera Solutions, China

End of Conference Day 3